Precision Therapeutics Against Solid Cancers

Welcome

At GANYMED, we are dedicated to the delivery of a new class of highly effective truly cancer specific ideal monoclonal antibody therapeutics (IMABs) against solid cancers with high medical need.

In order to do this, we have brought together the strongest and most dynamic scientific team for translational medicine.

We have generated a sustainable pipeline of IMABs that we are developing as high value therapeutics for solid cancers with huge unmet clinical need, such as gastric, oesophageal, pancreatic, breast, colorectal, prostate and lung cancer.


Business building

Contact Information:

GANYMED Pharmaceuticals AG
Freiligrathstrasse 12
55131 Mainz
GERMANY

Phone:
Fax:
E-Mail:

+49 / 6131 / 1440-100
+49 / 6131 / 1440-114
info[at]ganymed-pharmaceuticals.com


Business building
BioPhar Einkaufskooperation
BioPhar  purchasing co-operation



Cluster für individualisierte Immunintervention

News

[April 2011]

Gutenberg

Gutenberg tv:

gut geforscht - Wissenschaft vor Ort: Translationale Medizin

 

[August 2010]

Clinical Phase I Results of GANYMED’s IMAB362 Antibody Demonstrate Excellent Safety

 

Cluster

Ganymed belongs to CI3 - Cluster of

"individualized immunointervention -

ImmunoPolis"

Associations

Association for Cancer Immunotherapy

Biotechnologie-Industrie-Organisation Deutschland e.V.